What guidance did Orthopediatrics's management provide for the next earnings period?

What is Orthopediatrics's gross profit margin?

What factors drove the changes in Orthopediatrics's revenue and profit?

What were the key takeaways from Orthopediatrics’s earnings call?

What were the key takeaways from Orthopediatrics's earnings call?

What is Orthopediatrics's latest dividend and current dividend yield?

What does Orthopediatrics do and what are its main business segments?

What is the revenue and EPS growth rate for Orthopediatrics year over year?

- **Core Growth**: 17% T&D and 4% Scoliosis growth drove Q3 revenue, excluding 7D/LatAm headwinds.
- **Profitability Improvement**: EBITDA up 56% to $6.2M; free cash flow usage down 70% to $3.4M.
- **Strategic Focus**: Shifting to higher-margin implants and OPSB clinics, targeting 12%+ 2026 growth.
- **Competitive Advantage**: Major competitors exiting pediatric market, creating share gains.
- **Risk Management**: Reducing LatAm stocking to focus on profitable implants; diversifying international growth.
- **Pipeline Momentum**: 3P Hip launch ahead of schedule; NextGen spinal fusion system 2026-2027.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue of $61.2 million, up 12% YoY, driven by Trauma & Deformity (17% growth) and Scoliosis (4% growth). Excluding 7D capital and Latin America (LatAm) stocking, core revenue grew 17% globally and 19% domestically.
- **Key Product Performances**: 
  - T&D implants (e.g., PNP Femur, Tibia) saw strong adoption; 3P Pediatric Plating System launched ahead of schedule.
  - OPSB clinics expanded to 40+ locations, with 25% return on acquisitions and 40% for greenfield clinics.
  - Scoliosis implant sales grew despite delayed 7D unit placements.
- **Profitability**: Adjusted EBITDA improved 56% to $6.2 million; free cash flow usage decreased to $3.4 million (vs. $11.7M prior year).
- **Outlook**: Full-year 2025 revenue $233.5M-$234.5M, targeting 12%+ 2026 growth. Free cash flow breakeven by Q4 2025, $15M+ new set deployments.

**【CFO Financial Commentary】**
- **Financial Metrics**: 
  - GAAP net loss $0.50/share; Non-GAAP loss $0.24/share.
  - Gross margin 74%, up from 73% YoY.
  - Operating expenses $54.7M (+19%), driven by restructuring ($2.3M) and OPSB clinic growth.
- **Cash Position**: $59.8M in cash, short-term investments.
- **Guidance**: 2025 EBITDA $15M-$17M; 2026 free cash flow breakeven.

**【Q&A Highlights】**
- **Competitive Landscape**: Major competitors (J&J, Smith & Nephew) exiting pediatric-specific products, creating share opportunities.
- **LatAm Strategy**: Reduced focus on low-margin stocking/set sales to prioritize high-margin implant business.
- **Product Pipeline**: 3P Hip system launch in Q4 2025; NextGen spinal fusion system expected 2026-2027.
- **OPSB Expansion**: 12%+ baseline growth target, with 20+ new clinics planned annually.
- **Risk Mitigation**: Diversifying international growth (EMEA, APAC) to offset LatAm volatility.

OrthoPediatrics Corp. (KIDS) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

KIDS

KIDS fundamentals

You can ask Aime